Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
Drug guidance

Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis

Condition

Gastrointestinal tract

1 April 2020

Published on 01 Apr 2020
Last Updated on 01 Apr 2020

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing budesonide prolonged-release 9 mg tablet on the Medication Assistance Fund (MAF) for treating mild to moderate active ulcerative colitis because of uncertain comparative effectiveness and unfavourable cost effectiveness compared to alternative treatment options.

Budesonide for ulcerative colitis (1 Apr 2020) [PDF, 77 KB]

Budesonide for Ulcerative Colitis PES (1 Apr 2020) [PDF, 29 KB]

Back to top